CA209-7A8
03 Dec 2020
Trial Summary
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
Acronym:
CheckMate 7A8
ACTRN/NCT /ethics:
NCT04075604
Scientific title:
Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Palbociclib + Anastrozole
Sponsor / Cooperative group:
Bristol-Myers Squibb
Trial & Patient Characteristics
| Cancer Type | Breast |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2019-10-09 |
| Anticipated End Date | 2022-04-28 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |